Establishment Labs to Announce First Quarter 2024 Financial Results on...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: May 6, 2024

Las Vegas to Host WRESTLEMANIA® 41 Saturday, April 19 & Sunday, April 20, 2025 • Tennant Company Announces Senior Leadership Updates to Direct ERP Transformation and Drive Product Innovation • National Institutes of Health All of Us Research Program Mobile Tour Visits Rochester, NY • KB Home Announces the Grand Opening of Its Newest Community in Desirable Buckeye, Arizona • Ministers Anandasangaree, Hajdu, Vandal, and Ien issue statement on Red Dress Day 2024 • Preserving Holocaust remembrance and creating safer communities • i3 Verticals Announces Earnings Release and Conference Call Date for Second Quarter of Fiscal 2024 • Think Together Recognizes Colton Joint Unified School District as its 2024 Champion of Change • Brown Books Kids Publishes Children’s Picture Book, Perfect for Summer Reading • High School Women Launch First of its Kind Energy Literacy Podcast • Statement by Minister Khera on the occasion of Orthodox Easter • Preserving Sikh Canadian heritage and culture • Anaergia Announces Additional Delay in the Filing of Its Audited Financial Statements and Related Disclosures • Statement - Public Safety Minister • CORRECTING and REPLACING Babson Diagnostics Partners with Cynergy Wellness, Inc. • Robert Galibert Makes a Drug-Free French Connection on Voices for Humanity • Federal Reserve Board Gov. Lisa Cook gives keynote address at GCSU commencements • University of Phoenix College of Doctoral Studies Holds Third Annual Colloquium Supporting Doctoral Students • Christian & Timbers Releases Proprietary Study on C-Suite Compensation Trends in Cybersecurity Industry; Reveals CEO Compens • Statement by Minister Khera on Dutch Heritage Day

Establishment Labs to Announce First Quarter 2024 Financial Results on May 8

NEW YORK , April 24 /Businesswire/ - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.

To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13746251. The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and it is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva Implants® and began a clinical trial to support regulatory approval in the United States. Please visit our website for additional information at www.establishmentlabs.com.